ISMRM22 - From Basic Research to the End User: MR Biomarkers for Muscle & MSK Diseases

Joint Annual Meeting ISMRM-ESMRMB & ISMRT 31st Annual Meeting • 07-12 May 2022 • London, UK

From Basic Research to the End User: MR Biomarkers for Muscle & MSK Diseases

Member-Initiated Symposium

Monday, 09 May 2022

ICC Capital Hall 2

17:00 - 19:00

Moderators: Hermien Kan & Francesco Santini

Session Number: MIS-01

Organizers
Xeni Deligianni
Claudia Weidensteiner
Hermien Kan

Overview
Muscle MRI, and musculoskeletal MRI in general, is slowly emerging as a disease monitoring biomarker. However, reaching the level of using quantitative MRI (qMRI) outcomes as surrogate endpoints is not an obvious step. In fact, many innovative methods never reach application in the practice or in clinical trials, neither as clinical and diagnostic tools, nor as surrogate endpoints. The rarity and variability of some types of disease, the challenge of standardization between sites, on top of other issues, complicate and delay the translation of quantitative methods.
In this symposium, we aim to give a global perspective about the actual demands of producing a robust qMRI biomarker, be it for a clinical study or for a pilot industry study and to highlight the current limits that restrict Muscle/MSK qMRI outputs from being more used.
The MIS talks will cover different aspects starting from the clinical perspective, the application demands of a large study, the demands of the end user and the global perspective of quantitative MRI.
The session will consist of: 2 talks of 15 min, 4 of 10 min, and a panel discussion (45 min) with MR scientists, industry representatives and radiologists.

Target Audience
MRI method developers interested in translation; researchers from pharma industry; Radiologists performing clinical studies

Educational Objectives
As a result of attending this course, participants should be able to:
To understand issues, challenges and characteristics of different types of biomarkers. To learn how to bring a Muscle/ MSK MR biomarker to a level that is useful and applicable in studies and clinical practice. To learn the different perspectives for an eventual application to the clinic, to pilot studies or to clinical trials.

	17:00		Introduction
	17:05		Development of an MSK Imaging Biomarker, Insights From the QIBA Process Video Unavailable Thomas Link University of California, San Francisco, United States
	17:20		Muscle Fat Fraction as an Outcome in Multicenter Clinical Trials for Muscular Dystrophy Video Unavailable Rebecca Willcocks University of Florida, United States
	17:35		Translational Imaging for the Assessment of Therapies for Musculo-Skeletal Indications: Part I Video Unavailable Nicolau Beckmann Novartis Institutes for Bio Medical Researc, Switzerland
	17:45		Translational Imaging for the Assessment of Therapies for Musculo-Skeletal Indications: Part II Video Unavailable Didier Laurent Novartis Institutes for Bio Medical Researc, Switzerland
	17:55		MR Imaging Biomarker for the Evaluation of Efficacy of Cartilage Repair Therapies Video Unavailable Siegfried Trattnig High Field MR Center, Austria
	18:05		Perfusion MRI as Biomarker in Musculoskeletal Diseases Video Unavailable Rianne van den Heijden University of Wisconsin-Madison, United States
	18:15		Panel Discussion Video Unavailable Valentina Mazzoli¹, James MacKay², Esther Raithel³ Stanford University, United States¹, Astrazeneca, United Kingdom², Siemens, Germany³